STAT3 and psoriasis: Preclinical studies indicated that the use of the CK2-specific inhibitor CX-4945 (Silmitasertib) was able to reduce the epidermal hyperplasia in a model of imiquimod (IMQ)-induced psoriasis through STAT3 and Akt modulation [40] as well as by c-Myc downregulation, whose activity is also involved in keratinocyte proliferation [41].